USFDA inspection of Lupin's Vizag manufacturing facility completed without any adverse observation

13 Mar 2023 , 01:18 AM

Lupin announced on Friday that a pre-approval and good manufacturing practises (GMP) inspection of its active pharmaceutical ingredient (API) manufacturing facility in Visakhapatnam by the USFDA ended without any observations.

The inspection took place between March 6 to March 10, 2023.

Nilesh Gupta, Lupin’s managing director, expressed satisfaction with the successful inspection of their Vizag facility.

Gupta added that this achievement demonstrates their dedication to maintaining worldwide quality standards at all of their manufacturing locations, with the ultimate goal of delivering affordable healthcare of the highest quality to everyone.

At around 1.15 PM, Lupin was trading at Rs 653.85, against the previous close of Rs 656.10 on NSE. The counter touched an intraday high and low of Rs 664.95 and Rs 651.15 respectively.

For feedback and suggestions, write to us at [e-mail]